Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of active immunotherapy with CAP-1 (6D) and CMVpp65 peptide-pulsed, autologous dendritic cells produced in the aastromreplicell cell production system in patients with stage IV CEA expressing malignancies.

Next Previous
X
Search
Trial Profile

A phase I study of active immunotherapy with CAP-1 (6D) and CMVpp65 peptide-pulsed, autologous dendritic cells produced in the aastromreplicell cell production system in patients with stage IV CEA expressing malignancies.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CAP1-6D peptide vaccine (Primary) ; ITI 1000 (Primary)
  • Indications Cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Sep 2014 Biomarkers information updated
    • 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 20 Sep 2006 Status changed from recruiting to in progress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top